Measuring disease likelihood in genomic ascertainment

In this study, the likelihood that individuals with medically actionable secondary genomic variants were affected with hereditary cancer ranged from 26.2% to 100%. Over half (51%) met diagnostic criteria for testing, indicating underuse. Assessing the diagnostic yield and utility of secondary findings is crucial to inform policy development for population genomic screening.